GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Study of LY3532226 in Participants With Obesity

A Dose-Escalation Phase 1, Investigator- and Participant-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3532226 in Participants With Obesity

Lead sponsor

Eli Lilly and Company

Asset

Macupatide

Subcutaneous · GIP agonist

Listed sites

Recruiting sites

—

Enrollment

132

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI 30-40

Primary endpoint

•Treatment-emergent AEs (any) (Treatment-emergent AEs (any), Serious AEs (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06557356

Org study ID18835

Secondary IDJ2V-MC-GZLDEli Lilly and Company

Timeline

Milestones

Study first posted2024-08-16actual

Study start2024-08-16actual

Primary completion2025-12-12actual

Study completion2025-12-12actual

Last update posted2026-01-20actual

Assets

Investigational agents

Macupatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Have a body weight not exceeding 150 kilograms (kg) or 330 pounds (lb) and body mass index (BMI) within the range of 30 to 40 kilogram per square meter (kg/m²)

•Have had a stable body weight that is less than or equal to 5% change in body weight for 3 months prior to screening and enrollment

Exclusion criteria

•Have a lifetime history of a suicide attempt

•Have a history or presence of psychiatric disorders, including a history of major depressive disorder within the last 2 years

•Have a baseline Patient Health Questionnaire-9 (PHQ-9) score of 15 or greater, and/or a score of 2 or greater for either of the first 2 questions on the PHQ-9 questionnaire

•Have a known clinically significant gastric emptying abnormality, have undergone gastric bypass surgery or restrictive bariatric surgery

•Have taken approved or investigational medication for weight loss, within the previous 3 months or 5 half-lives of study screening, whichever is earlier

•Intend to use any weight-loss medications during study participation

•Have obesity induced by other endocrinologic disorders or diagnosed monogenetic or syndromic forms of obesity

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Glycemic / diabetes

1 endpoint

Secondary/protocol endpoint

Part C: Pharmacodynamic (PD): Change in insulin sensitivity index (Si)

Time frame:Baseline up to Approximately Week 4

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Safety / tolerability / PK

7 endpoints

Primary/protocol endpoint

Part A: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline to Study Completion (Up to 16 Weeks)

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Primary/protocol endpoint

Part B: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline to Study Completion (Up to 20 Weeks)

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Primary/protocol endpoint

Part C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline to Study Completion (Up to 8 Weeks)]

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Secondary/protocol endpoint

Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3532226

Time frame:Predose on Day 1 through Week 16

Cmax

concentration, descriptive

Secondary/protocol endpoint

Part A: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3532226

Time frame:Predose on Day 1 through Week 16

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

Part B: PK: Cmax of LY3532226

Time frame:Predose on Day 1 through Week 20

Cmax

concentration, descriptive

Secondary/protocol endpoint

Part B: PK: AUC of LY3532226

Time frame:Predose on Day 1 through Week 20

AUC₀–∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.